Healthcare, biotechnology & medical AI Product
Us2.ai has distinct FDA clearances for two echocardiography tools
Us2.v1 extracts cardiac measurements from transthoracic ultrasound images. Us2.ca uses that imaging modality for a separate, specifically labeled role supporting the evaluation of cardiac amyloidosis. [1][2]
What it does
The FDA cleared Us2.v1 under K210791 on July 27, 2021, and Us2.ca under K250151 on June 20, 2025. The FDA records list distinct device names and indications. [1][2]
Why it matters
The clearance records distinguish measurement and reporting software from a separate adjunctive tool developed for a specific evaluation question. [1][2]
Who it’s for
The published indications address qualified providers involved in reviewing echocardiographic images. [1][2]
Key dates
Where it fits
Us2.v1 produces a structured set of measurements from acquired images. Us2.ca has its own labeled output and evaluation scope. [1][2]
Limits and trade-offs
The specific population and role in the Us2.ca filing apply to that device. The Us2.v1 clearance describes a different function. [1][2]
Sources and verification
Catalog evidence checked How we verify records
- Primary source FDA 510(k) decision for Us2.ca (K250151)
- Primary source FDA 510(k) decision for Us2.v1 (K210791)
Related profiles
Healthcare, biotechnology & medical AI
Sleep Analysis Module (SAM)
Neurotronics (Nihon Kohden)
The module estimates sleep time from a signal captured during its intended sleep-testing workflow.
Healthcare, biotechnology & medical AI
Heartvue.Proton
Heartvue.ai
It is software for analyzing cardiac MRI images within its documented intended-use scope.
Healthcare, biotechnology & medical AI
ThinkSono Guidance
ThinkSono
Provides guidance during acquisition of lower-extremity compression ultrasound images for review by healthcare professionals.